Lennard P. L. Gilissen - Search Results

Year	Number of Results
2003	1
2004	2
2005	1
2006	2
2010	1
2011	2
2012	1
2013	1
2015	1
2016	4
2017	2
2018	2
2019	2
2020	2
2021	6
2022	1
2023	5
2024	1

1

Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment-TUMMY Study.

Sivridaş M, Creemers RH, Wong DR, Boekema PJ, Römkens TEH, Gilissen LPL, van Bodegraven AA, Loeff FC, Rispens T, Derijks LJJ. Sivridaş M, et al. Among authors: gilissen lpl. Pharmaceutics. 2023 Mar 17;15(3):972. doi: 10.3390/pharmaceutics15030972. Pharmaceutics. 2023. PMID: 36986833 Free PMC article.

2

Standard of Care Versus Octreotide in Angiodysplasia-Related Bleeding (the OCEAN Study): A Multicenter Randomized Controlled Trial.

Goltstein LCMJ, Grooteman KV, Bernts LHP, Scheffer RCH, Laheij RJF, Gilissen LPL, Schrauwen RWM, Talstra NC, Zuur AT, Braat H, Hadithi M, Brouwer JT, Nagengast WB, Oort FA, Tenthof van Noorden J, Kievit W, van Geenen EJM, Drenth JPH. Goltstein LCMJ, et al. Among authors: gilissen lpl. Gastroenterology. 2024 Apr;166(4):690-703. doi: 10.1053/j.gastro.2023.12.020. Epub 2023 Dec 28. Gastroenterology. 2024. PMID: 38158089 Free article. Clinical Trial.

3

Algorithm combining virtual chromoendoscopy features for colorectal polyp classification.

Schreuder RM, van der Zander QEW, Fonollà R, Gilissen LPL, Stronkhorst A, Klerkx B, de With PHN, Masclee AM, van der Sommen F, Schoon EJ. Schreuder RM, et al. Among authors: gilissen lpl. Endosc Int Open. 2021 Sep 16;9(10):E1497-E1503. doi: 10.1055/a-1512-5175. eCollection 2021 Oct. Endosc Int Open. 2021. PMID: 34540541 Free PMC article.

4

Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel Disease.

Crouwel F, Simsek M, de Boer MA, Mulder CJJ, van Andel EM, Creemers RH, van Asseldonk DP, van Bodegraven AA, Horjus CS, Visschedijk MC, Weusthuis ALM, Seinen ML, Jharap B, van Schaik FDM, Ahmad I, Boekema PJ, Tack GJ, Wormmeester L, Lutgens MWMD, van Boeckel PGA, Gilissen LPL, Kerkhof M, Russel MGVM, Hoentjen F, Bartelink ME, Kuijvenhoven JP, Maljaars JWJ, van Dop WA, Wonders J, van der Voorn MMPJA, Buiter HJC, de Boer NK. Crouwel F, et al. Among authors: gilissen lpl. J Crohns Colitis. 2023 May 3;17(5):738-745. doi: 10.1093/ecco-jcc/jjac183. J Crohns Colitis. 2023. PMID: 36521000 Free PMC article.

5

Crystallization in the waterjet channel in colonoscopes due to simethicone.

van Stiphout SH, Laros IF, van Wezel RA, Gilissen LP. van Stiphout SH, et al. Among authors: gilissen lp. Endoscopy. 2016 0;48(S 01):E394-E395. doi: 10.1055/s-0042-120261. Epub 2016 Dec 2. Endoscopy. 2016. PMID: 27912222 No abstract available.

6

Relapse rates after withdrawal versus maintaining biologic therapy in IBD patients with prolonged remission.

Stoker AMH, Logghe L, van der Ende-van Loon MCM, Schoon EJ, Schreuder RM, Stronkhorst A, Gilissen LPL. Stoker AMH, et al. Among authors: gilissen lpl. Clin Exp Med. 2023 Oct;23(6):2789-2797. doi: 10.1007/s10238-023-00994-6. Epub 2023 Jan 12. Clin Exp Med. 2023. PMID: 36633694 Free PMC article.

7

Translation, validation and psychometric properties of the Dutch version of the Inflammatory Bowel Disease-Fatigue (IBD-F) self-assessment scale.

Stoker AMH, Gruters A, Loon MCMVE, Postulart D, Czuber-Dochan W, Gilissen LPL. Stoker AMH, et al. Among authors: gilissen lpl. J Patient Rep Outcomes. 2023 Oct 30;7(1):108. doi: 10.1186/s41687-023-00642-3. J Patient Rep Outcomes. 2023. PMID: 37902851 Free PMC article.

8

Costs of Leaks and Bleeding After Sleeve Gastrectomies.

Bransen J, Gilissen LP, van Rutte PW, Nienhuijs SW. Bransen J, et al. Among authors: gilissen lp. Obes Surg. 2015 Oct;25(10):1767-71. doi: 10.1007/s11695-015-1584-z. Obes Surg. 2015. PMID: 25636733

9

The prevalence of nodular regenerative hyperplasia of the liver in long-term thiopurine-treated inflammatory bowel disease patients.

Gilissen LPL, Tajzai R, Romberg M, Pierik M, Stronkhorst A, Steenhuisen K, Van Bodegraven A, Daniels A, Wong D. Gilissen LPL, et al. Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e102-e107. doi: 10.1097/MEG.0000000000001980. Eur J Gastroenterol Hepatol. 2021. PMID: 33136726

10

Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease.

Mahmmod S, Schultheiss JPD, van Bodegraven AA, Dijkstra G, Gilissen LPL, Hoentjen F, Lutgens MWMD, Mahmmod N, van der Meulen-de Jong AE, Smits LJT, Tan ACITL, Oldenburg B, Fidder HH. Mahmmod S, et al. Among authors: gilissen lpl. Inflamm Bowel Dis. 2021 Nov 15;27(12):1954-1962. doi: 10.1093/ibd/izaa364. Inflamm Bowel Dis. 2021. PMID: 33538298

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

33 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year